Compare Blackstone Inc (BX) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blackstone Inc vs Danaher Corporation — how do they compare? Blackstone Inc trades at $147.17 (market cap $113.32B), while Danaher Corporation trades at $207.4 (market cap $147.18B). The key difference: Danaher Corporation is the larger of the two by market cap, and Blackstone Inc pays the higher dividend (3.69%). Which is the better fit depends on your goals.
| BX | DHR | |
|---|---|---|
Market Cap | $113.32B | $147.18B |
Sector | Financials | Health |
52-Week High | $188.68 | $242.05 |
52-Week Low | $102.12 | $161.91 |
Dividend Yield | 3.69% | 0.76% |
Enterprise Value | — | $169.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blackstone Inc. (BX) trades at $137.13, up 2.76% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $12.41 billion in 2025, with a net income margin of 25.85%, while analyst consensus is a Buy with a $144.00 price target. Recent news includes a $16 billion Kuwait oil pipeline deal and the acquisition of a $25.3 billion Australian loan portfolio from HSBC, highlighting strategic expansion.
The outlook for BX is positive, driven by robust earnings growth and strategic acquisitions, but risks include market volatility and sector-specific pressures. Upside potential exists toward the consensus target, though overbought RSI levels near-term may prompt consolidation.
Danaher (DHR) trades at $207.44, up 1.31% today, near its pivot point of $207. The stock exhibits a bullish technical trend, supported by moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company maintains strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights the acquisition of Masimo and new product launches from its SCIEX unit, signaling growth initiatives.
The outlook remains positive with analyst consensus favoring a Buy rating and a $202.33 price target, though the current price exceeds this. Risks include a high P/E ratio of 37.32 and ongoing legal settlements, but robust cash flow and institutional accumulation provide support. Earnings growth in the biotechnology segment is a key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
